study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
INFL-INF15-01,2010,randomized controlled trial,SMD,-0.2012,-0.3347,-0.0677,86,96,some concerns,10.1234/infl-inf15-01,inflammation-journal-01,skin_inflammation,Adults with skin inflammation concerns,Mild GI discomfort,13
INFL-INF15-02,2015,randomized controlled trial,SMD,-0.1958,-0.3817,-0.0099,99,80,mixed,10.1234/infl-inf15-02,inflammation-journal-02,skin_inflammation,Adults with skin inflammation concerns,Mild GI discomfort,12
INFL-INF15-03,2020,randomized controlled trial,SMD,-0.1904,-0.3588,-0.022,82,95,mixed,10.1234/infl-inf15-03,inflammation-journal-03,skin_inflammation,Adults with skin inflammation concerns,None reported,10
